Pay in 4 interest-free payments of $7.26 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Analysis of nearly 8,000 adults found 45% keep the weight off after one year As the use of injectable GLP-1 drugs continues to rise, questions persist about what happens after patients stop taking them in real-world settings
#Retatrutide #Obesity #WeightManagement #Diabetes #GLP1 #GIP #MetabolicHealth #Endocrinology #ClinicalResearch #HealthcareInnovation #Pharmacy To view or add a comment, sign in ' Eli Lilly and Company has announced positive topline results from two additional Phase III trials of retatrutide, its investigational first-in-class GIP/GLP-1/glucagon triple receptor agonist for obesity and related metabolic conditions
Youll usually stay on this dose for at least 4 weeks before moving to 7.5 mg, depending on how you feel and your clinicians advice
Acute Kidney Injury: Gastrointestinal side effects of Zepbound (tirzepatide) like diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems if dehydration is severe
Individual genetic variations in GLP1R gene expression may explain why some patients achieve optimal results at lower doses while others require higher amounts for comparable weight loss
